LeMaitre Vascular (LMAT) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
LeMaitre Vascular (LMAT) has outperformed Stereotaxis (STXS) over the past year, losing 9.5% versus a loss of 64.5%. Over five years, LMAT leads with a +48.6% price change compared with -80.9% for STXS. LeMaitre Vascular is the larger company by market cap ($1.82 billion vs $111.2 million), about 16.4 times the size.
LeMaitre Vascular pays a dividend yielding 1.13%, while Stereotaxis does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LMAT | STXS |
|---|---|---|
| Share price | $79.64 | $1.11 |
| Market cap | $1.82B | $111.22M |
| 1-day change | +0.42% | -1.77% |
| YTD return | -1.80% | -50.87% |
| 1-year return | -9.54% | -64.47% |
| 5-year return | +48.64% | -80.94% |
| P/E ratio (TTM) | 27.94 | — |
| Forward P/E | 25.05 | — |
| EPS (TTM) | $2.85 | $-0.24 |
| Dividend yield | 1.13% | 0.00% |
| Annual dividend | $0.90 | $0.00 |
| Revenue (latest FY) | $249.60M | — |
| Revenue growth (YoY) | +13.53% | — |
| Net income (latest FY) | $57.73M | — |
| Gross margin | 71.53% | — |
| Operating margin | 27.21% | — |
| Net margin | 23.13% | — |
| 52-week high | $118.01 | $3.42 |
| 52-week low | $78.22 | $1.09 |
| Distance from 52-week high | -32.51% | -67.54% |
| Analyst consensus | buy | none |
| Avg. price target upside | +34.35% | +170.27% |
| Average volume | 330.14K | 808.41K |
| Shares outstanding | 22.87M | 100.20M |
| Employees | 646 | 131 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Medical Instruments & Supplies |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LeMaitre Vascular is about 16.4 times larger than Stereotaxis by market value ($1.82B vs $111.22M).
- LMAT has outperformed STXS by 54.9 percentage points over the past year.
- LeMaitre Vascular offers a meaningfully higher dividend yield (1.13% vs 0.00%).
About LeMaitre Vascular
LMAT stock →LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.
Healthcare · Medical Instruments & Supplies · 646 employees
About Stereotaxis
STXS stock →Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Healthcare · Medical Instruments & Supplies · 131 employees
LMAT vs STXS FAQ
Which is bigger, LeMaitre Vascular or Stereotaxis?
LeMaitre Vascular (LMAT) is larger, with a market capitalization of $1.82B compared with $111.22M for Stereotaxis (STXS).
Which stock has performed better over the past year, LMAT or STXS?
LMAT returned -9.54% over the past 12 months, compared with -64.47% for STXS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, LeMaitre Vascular or Stereotaxis?
LeMaitre Vascular pays a dividend yielding 1.13%, while Stereotaxis does not currently pay a regular dividend.
Are LeMaitre Vascular and Stereotaxis in the same industry?
Yes. Both are classified in the Medical Instruments & Supplies industry within the Healthcare sector.